Immunocore Q1 KIMMTRAK sales $70.3M (+36% YoY); brenetafusp ASCO data; cash $832.8M

Immunocore Holdings plc

2024-Q1 EPS reported -$0.49 revenue$70,502,000

KIMMTRAK net sales $70.3M, up 36% YoY; US $50.0M, Europe $19.0M, international $1.4M.
Net loss $24.4M ($0.49/sh) vs $19.4M ($0.40/sh) in Q1 2023; R&D $57.5M, SG&A $39.3M.
Cash $832.8M as of Mar 31, 2024, including $390.2M net from Feb 2024 convertible notes; plans to repay $50M loan.
Brenetafusp Phase 1/2 data in late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (May 31).
KIMMTRAK launched in 7 additional countries since Jan 2024; now in 17 countries.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunocore Holdings plc reported the first quarter ended March 31, 2024 results: revenue Total net product revenue ... was $70.3 million in the first quarter of 2024, net income Net loss for the first quarter of 2024 was $24.4 million, EPS The first quarter basic and diluted loss per share was $0.49.

Period: the first quarter ended March 31, 2024
Revenue: Total net product revenue ... was $70.3 million in the first quarter of 2024
Net income: Net loss for the first quarter of 2024 was $24.4 million
EPS: The first quarter basic and diluted loss per share was $0.49
Result: reported results

Exact text from the filing

On May 8, 2024, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024, as well as other recent corporate updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunocore Holdings plc filing history →

Source: SEC EDGAR

accession 0001140361-24-024789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.